Sam Brusco, Associate Editor08.24.22
Roche has launched the Digital LightCycler system, the company’s first digital polymerase chain reaction (PCR) system.
The system spots disease and can accurately quantify trace amounts of DNA and RNA targets not usually detectable by conventional PCR methods. Clinical researchers can divide DNA and RNA from an extracted sample into as many as 100,000 microscopic individual reactions.
The system then performs PCR and generates sophisticated data analysis of the results.
"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," Thomas Schinecker, CEO of Roche Diagnostics told the press. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."
The Digital LightCycler system offers new opportunities for oncology and infectious disease researchers beyond traditional PCR’s abilities, the company said—including rare targets, quantification of target DNA/RNA at a molecular level, and other high precision analysis.
Roche said the system will be available in 15 countries in 2022, with plans to roll out in more countries in the near future. It will be CE marked and has an FDA 510(k) exempt status.
The system spots disease and can accurately quantify trace amounts of DNA and RNA targets not usually detectable by conventional PCR methods. Clinical researchers can divide DNA and RNA from an extracted sample into as many as 100,000 microscopic individual reactions.
The system then performs PCR and generates sophisticated data analysis of the results.
"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," Thomas Schinecker, CEO of Roche Diagnostics told the press. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."
The Digital LightCycler system offers new opportunities for oncology and infectious disease researchers beyond traditional PCR’s abilities, the company said—including rare targets, quantification of target DNA/RNA at a molecular level, and other high precision analysis.
Roche said the system will be available in 15 countries in 2022, with plans to roll out in more countries in the near future. It will be CE marked and has an FDA 510(k) exempt status.